Defective SREBP-1c signaling may explain the decreased differentiationand insulin resistance of PI-treated cells and the ability of PPARγ agonists to overcome the PI effects on fatcell differentiation and insulin response [21]. This evidence concerns the gene SREBF1 and Insulin resistance.